KVUE Stock Analysis: Kenvue | NYSE
Household & Personal Products | NYSE, USA | Market Cap: 36.096m USD | 12M Return: -4.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 380M
EPS Trend: -82.8%
Qual. Beats: 1
Rev. Trend: -75.9%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 3.1 years of data
Average return per month, with how dependable it is below — did the month move the same way every year (high) or randomly (low). Above 60 is a pattern worth trusting; under 40 is noise.
Kenvue Inc. (NYSE: KVUE) is a global consumer health company headquartered in Summit, New Jersey. Incorporated in 2022 and listed via IPO on May 4, 2023, the company operates across the United States, rest of North America, Europe, the Middle East, Africa, Asia-Pacific, and Latin America.
The business is organized into three reportable segments: Self Care, Skin Health and Beauty, and Essential Health. Its product portfolio spans over-the-counter medicines (cough, cold, allergy, pain, digestive health, smoking cessation, and eye care), face, body, hair, and sun care products, oral care, baby care, womens health, wound care, tampons, cosmetics, and vitamins and supplements.
Kenvue sells its products under well-established brands including Tylenol, Benadryl, Motrin, Zyrtec, Nicorette, Calpol, Rhinocort, and Zarbees Naturals in Self Care; Neutrogena, Aveeno, Lubriderm, OGX, Dr.Ci:Labo, Le Petit Marseillais, and Rogaine in Skin Health and Beauty; and Band-Aid, Johnsons, Listerine, Neosporin, Desitin, o.b., Stayfree, and Pepcid in Essential Health, among others.
Within the GICS classification, KVUE is categorized under Consumer Staples, specifically the Personal Care Products sub-industry. The company was created through the spin-off of Johnson & Johnsons consumer health segment, which separated the faster-growing consumer products from J&Js pharmaceutical and medical devices businesses. As a consumer staples issuer, Kenvues revenue tends to be relatively defensive, supported by essential everyday health and personal care categories rather than discretionary spending.
- Tylenol and Zyrtec Self Care segment faces Haleon competition
- Skin Health and Beauty margins pressured by Neutrogena promotional spending
- Dividend and buyback program supports post-JNJ spinoff valuation
| Net Income: 1.62b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 1.27 > 1.0 |
| NWC/Revenue: -0.66% < 20% (prev -6.25%; Δ 5.59% < -1%) |
| CFO/TA 0.08 > 3% & CFO 2.26b > Net Income 1.62b |
| Net Debt (7.73b) to EBITDA (3.17b): 2.44 < 3 |
| Current Ratio: 0.98 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.92b) vs 12m ago -0.16% < -2% |
| Gross Margin: 58.37% > 18% (prev 58.06%; Δ 0.31% > 0.5%) |
| Asset Turnover: 57.59% > 50% (prev 58.28%; Δ -0.69% > 0%) |
| Interest Coverage Ratio: 6.63 > 6 (EBIT TTM 2.61b / Interest Expense TTM 393.0m) |
| A: -0.00 (Total Current Assets 5.79b - Total Current Liabilities 5.90b) / Total Assets 26.9b |
| B: -0.00 (Retained Earnings -128.0m / Total Assets 26.9b) |
| C: 0.10 (EBIT TTM 2.61b / Avg Total Assets 26.6b) |
| D: 0.65 (Book Value of Equity 10.6b / Total Liabilities 16.2b) |
| Altman-Z'' = 1.30 = BB |
| DSRI: 1.03 (Receivables 2.91b/2.82b, Revenue 15.3b/15.3b) |
| GMI: 0.99 (GM 58.06% / 58.37%) |
| AQI: 0.99 (AQ_t 0.70 / AQ_t-1 0.71) |
| SGI: 1.00 (Revenue 15.3b / 15.3b) |
| TATA: -0.02 (NI 1.62b - CFO 2.26b) / TA 26.9b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of June 30, 2026, the stock is trading at USD 19.07 with a total of 21,083,694 shares traded. Over the past week, the price has changed by +5.57%, over one month by +8.45%, over three months by +12.30% and over the past year by -4.35%.
Current recommended Stop Loss: 18.60 (which is 2.5% or 1.3 ATR below the current price).
Kenvue has received a consensus analysts rating of 3.42. Therefore, it is recommended to hold KVUE.
- StrongBuy: 3
- Buy: 2
- Hold: 14
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 19.5 | 2.3% |
P/E Trailing = 22.381
P/E Forward = 16.3399
P/S = 2.3605
P/B = 3.4027
P/EG = 1.5569
Revenue TTM = 15.3b USD
EBIT TTM = 2.61b USD
EBITDA TTM = 3.17b USD
Long Term Debt = 7.07b USD (from longTermDebt, last quarter)
Short Term Debt = 1.59b USD (from shortTermDebt, last quarter)
Debt = 8.80b USD (from shortLongTermDebtTotal, last quarter) + Leases 141.0m
Net Debt = 7.73b USD (calculated: Debt 8.80b - CCE 1.07b)
Enterprise Value = 43.8b USD (36.1b + Debt 8.80b - CCE 1.07b)
Interest Coverage Ratio = 6.63 (Ebit TTM 2.61b / Interest Expense TTM 393.0m)
EV/FCF = 24.04x (Enterprise Value 43.8b / FCF TTM 1.82b)
FCF Yield = 4.16% (FCF TTM 1.82b / Enterprise Value 43.8b)
FCF Margin = 11.92% (FCF TTM 1.82b / Revenue TTM 15.3b)
Net Margin = 10.61% (Net Income TTM 1.62b / Revenue TTM 15.3b)
Gross Margin = 58.37% ((Revenue TTM 15.3b - Cost of Revenue TTM 6.37b) / Revenue TTM)
Gross Margin QoQ = 58.89% (prev 56.53%)
Tobins Q-Ratio = 1.63 (Enterprise Value 43.8b / Total Assets 26.9b)
Interest Expense / Debt = 4.46% (Interest Expense 393.0m / Debt 8.80b)
Taxrate = 26.71% (591.0m / 2.21b)
NOPAT = 1.91b (EBIT 2.61b * (1 - 26.71%))
Current Ratio = 0.98 (Total Current Assets 5.79b / Total Current Liabilities 5.90b)
Debt / Equity = 0.83 (Debt 8.80b / totalStockholderEquity, last quarter 10.6b)
Debt / EBITDA = 2.44 (Net Debt 7.73b / EBITDA 3.17b)
Debt / FCF = 4.24 (Net Debt 7.73b / FCF TTM 1.82b)
Total Stockholder Equity = 10.7b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.11% (Net Income 1.62b / Total Assets 26.9b)
RoE = 15.18% (Net Income TTM 1.62b / Total Stockholder Equity 10.7b)
RoCE = 14.68% (EBIT 2.61b / Capital Employed (Equity 10.7b + L.T.Debt 7.07b))
RoIC = 8.77% (NOPAT 1.91b / Invested Capital 21.8b)
WACC = 4.61% (E(36.1b)/V(44.9b) * Re(4.94%) + D(8.80b)/V(44.9b) * Rd(4.46%) * (1-Tc(0.27)))
Discount Rate = 4.94% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 23.00 | Cagr: 0.16%
[DCF] Terminal Value 77.97% ; FCFF base≈1.67b ; Y1≈1.92b ; Y5≈2.82b
[DCF] Fair Price = 18.11 (EV 42.5b - Net Debt 7.73b = Equity 34.8b / Shares 1.92b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -82.76 | EPS CAGR: -16.66% | SUE: 2.23 | # QB: 1
Revenue Correlation: -75.94 | Revenue CAGR: -0.94% | SUE: 0.78 | # QB: 0
EPS next Quarter (2026-09-30): EPS=0.30 | Chg30d=+2.02% | Revisions=+27% | Analysts=9
EPS current Year (2026-12-31): EPS=1.19 | Chg30d=-0.08% | Revisions=+60% | GrowthEPS=+10.1% | GrowthRev=+3.3%
EPS next Year (2027-12-31): EPS=1.24 | Chg30d=+0.46% | Revisions=+43% | GrowthEPS=+4.0% | GrowthRev=+2.5%
[Analyst] Revisions Ratio: +60%